The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
URSODOX GH/ URSODOX LAPL (Generic Health Pty Ltd)
Product name
URSODOX GH/ URSODOX LAPL
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
168 (255 working days)
Active ingredients
Ursodeoxycholic acid
Registration type
New generic medicine
Indication
URSODOX LAPL/ URSODOX GH capsules are indicated in the treatment of chronic cholestatic liver diseases.